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ABSTRACT
Objective To assess whether screening for prostate
cancer reduces prostate cancer specific mortality.
Design Population based randomised controlled trial.
Setting Department of Urology, Norrköping, and the
South-East Region Prostate Cancer Register.
Participants All men aged 50-69 in the city of Norrköping,
Sweden, identified in 1987 in the National Population
Register (n=9026).
Intervention From the study population, 1494 men were
randomly allocated to be screened by including every
sixth man from a list of dates of birth. These men were
invitedtobescreenedeverythirdyearfrom1987to1996.
On the first two occasions screening was done by digital
rectal examination only. From 1993, this was combined
with prostate specific antigen testing, with 4 µg/L as cut
off. On the fourth occasion (1996), only men aged 69 or
under at the time of the investigation were invited.
Main outcome measures Data on tumour stage, grade,
andtreatmentfromtheSouthEastRegionProstateCancer
Register. Prostate cancer specific mortality up to 31
December 2008.
Results In the four screenings from 1987 to 1996
attendance was 1161/1492 (78%), 957/1363 (70%),
895/1210 (74%), and 446/606 (74%), respectively.
There were 85 cases (5.7%) of prostate cancer diagnosed
in the screened group and 292 (3.9%) in the control
group. The risk ratio for death from prostate cancer in the
screening group was 1.16 (95% confidence interval 0.78
to 1.73).In a Cox proportional hazardanalysis comparing
prostate cancer specific survival in the control group with
thatinthescreenedgroup,thehazardratiofordeathfrom
prostate cancer was 1.23 (0.94 to 1.62; P=0.13). After
adjustment for age at start of the study, the hazard ratio
was 1.58 (1.06 to 2.36; P=0.024).
Conclusions After 20 years of follow-up the rate of death
from prostate cancer did not differ significantly between
men in the screening group and those in the control
group.
Trial registration Current Controlled Trials,
ISRCTN06342431.
INTRODUCTION
Thefavourableoutcomeafterradicalsurgeryshownin
a Scandinavian study comparing radical prostatect-
omy with watchful waiting
1 has stimulated the debate
on early detection of prostate cancer, in particular by
testing for prostate specific antigen. The Prostate,
Lung, Colorectal, and Ovarian (PLCO) Cancer
Screening Trial
2 and the European Randomised
Study of Screening for Prostate Cancer (ERSPC)
3
were expected to provide final evidence for or against
screening as a method to reduce mortality from pros-
tate cancer. These two large studies, however, did not
show unequivocal benefit from prostate specific anti-
gen screening. The ERSPC trial showed a significant
improvementincancerspecificsurvivalformeninthe
screened group but with a high risk of overdiagnosis
and overtreatment.
3 The Gothenburg randomised
population based prostate cancer screening trial,
4
from one of the centres included in the ERSPC trial,
found a risk ratio for prostate cancer specific death
similar to that found in the ERSPC trial. The PLCO
trial, on the other hand, did not show any benefit from
screening,
2probablybecauseofalargedegreeofcross-
over contamination. Follow-up in the PLCO might
also have been too short to provide reliable data on
mortality.
In 1987 a randomised controlled trial on screening
forprostatecancerwasstartedinNorrköping,Sweden.
The study was started before prostate specific antigen
testing was established as a method of screening so at
thefirsttwoscreeningsessionsonlydigitalrectalexam-
ination wasused. From1993 this wascombined with a
prostatespecificantigentest.Thefeasibilityofascreen-
ing programme for prostate cancer has previously
been reported.
5 We have also previously presented
data on the reliability of digital rectal examination,
6
the cost effectiveness of screening for prostate
cancer,
78and the clinical consequences of screening.
9
Here we report on mortality 20 years after the start of
study.
METHODS
Thedesignofthestudyhasbeendescribedelsewhere.
9
In 1987 all men aged 50-69 in Norrköping, Sweden,
were identified in the National Population Register.
The total study population was 9026 men. From this
population, 1494 men were randomly allocated to be
screened by including every sixth man from a list of
dates of birth. The 7532 remaining men constituted
the control group. All men in the study group were
contacted by mail one week before each examination.
Information regarding the study was also spread by
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to assess the acceptance and feasibility of a prostate
cancer screening programme.
At the first screening session in 1987 a specialist in
urology and a general practitioner performed the digi-
tal rectal examinations. This double examination was
done to determine the reliability of the examination
between observers.
6 At subsequent sessions only gen-
eral practitioners performed the examinations. At the
third and fourth screening sessions, in 1993 and 1996,
digital rectal examination was combined with a test for
prostatespecificantigen,withconcentrationsof>4µg/
L as the cut off. With the exception of men who had
emigrated, the cohort allocated to screening remained
the same for the first three sessions. In the fourth ses-
sion,onlymenaged69orunderatthetimeoftheinves-
tigation were invited, which left a total of 606 men. All
men, including those who did not participate in the
fourth session, were included in the final analysis.
When the results of the digital rectal examination or
prostate specific antigen test led to a suspicion of pros-
tate cancer, the man underwent fine needle aspiration
biopsy. The biopsy samples were taken from the per-
ipheral zone of the apex, mid-prostatic region, and
basesof bothlaterallobesaccordingto a sextantdistri-
bution. Directed biopsy samples were also taken in
men in whom a nodule was palpated. If the biopsy
result was negative, information was sent by mail.
Men with positive cytology result were followed up
by a urologist and treated according to the standar-
dised management programme in the region. Investi-
gationsofmenwithprostatecancerincludedtestingfor
prostate specific antigen, transrectal ultrasonography,
andbonescan.Dependingonthetumourstageandthe
general condition of the patient, men were offered
radiotherapy or radical prostatectomy if it was consid-
ered possible to prolong survival.
The trial was made possible by the system of perso-
nal registration numbers,
10 each number being unique
for each Swedish citizen, making it possible to trace all
participants in the study in the population register, the
South-East Region Prostate Cancer Register, and the
Central Death Register.
11
All cases of prostate cancer, whether detected in the
screened or in the non-screened cohort, were regis-
tered in the South-East Region Prostate Cancer Regis-
ter.ThisregisterisanextensionoftheNationalCancer
Register, which was founded in 1958 to enable contin-
uous surveillance of the incidence of all oncological
diseases. The personal registration numbers are used
tolinktheSouth-EastRegionProstateCancerRegister
with the National Cancer Register. Whenever a new
case of prostate cancer is registered in the South-East
Region, the physician responsible for the patient sub-
mits a report according to a standardised protocol,
including tumour stage according to the tumour,
node, metastases (TNM) classification, tumour grade,
and treatment, to the regional oncological centre for
recording in the South-East Region Prostate Cancer
Register.
Figure 1 shows the trial enrolment and study group
assignment. Date of diagnosis, TNM categories,
tumour grade, and treatment were registered in the
South-East Region Prostate Cancer Register for all
menwithadiagnosisofprostatecancerinthescreened
and the non-screened cohort. All patients with cancer
were treated according to a standardised management
programme for prostate cancer common to the South
East Region. Date and cause of death were also
All men in Norrköping aged 50-69 in 1987 without diagnosis of prostate cancer (n=9026)
Every sixth man randomised to screening
Follow-up of survival up to 31 December 2008
Intervention group (n=1494)
Screening with DRE in 1987 (n=1161),
13 cancers detected at screening
Screening with DRE in 1990 (n=957),
7 cancers detected at screening
Control group (n=7532)
Cancers detected in
control group up to
31 December 1999 (n=292)
Interval cancers (n=42)
Interval cancers (n=5)
Cancers detected
at screening (n=43)
Screening with DRE and PSA in 1993 (n=895),
17 cancers detected at screening
Follow-up of cancers detected up to 31 December 1999
Screening with DRE and PSA in 1996, only men
aged <70 (n=606), 6 cancers detected at screening
Interval cancers (n=8)
Interval cancers (n=5)
Interval cancers (n=24)
Fig 1 | Flow chart of study group enrolment. DRE=digital rectal examination, PSA=prostate
specific antigen
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Fig 2 | Kaplan-Meier curves of overall survival for men
diagnosed with prostate cancer in control group (n=292) and
screened group (n=85). Log rank test P=0.14
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Death Register was checked for deaths not registered
in the South-East Region Prostate Cancer Register. In
September 2009 cause of death was registered in a
blinded review of the patients’ records for all men
who died. All men in whom cancer was diagnosed up
to 31 December 1999 were included in the analysis.
Survival was followed until 31 December 2008.
Statistics
All analyses were performed based on intention to
screen comparisons. We used Cox proportional
hazard modelling to estimate hazard ratios for death
from prostate cancer, with age and group allocation
(screening/control) as covariates. To investigate
whether the detection rate and subsequent mortality
changedaftertheintroductionofprostatespecificanti-
gen testing as a screening tool, we also tested a model
with diagnosis before 1993 versus diagnosis after 1993
as a dichotomous time varying covariate. We used log
ranktotestdifferencesintotalandprostatecancerspe-
cific survival. The difference in deaths from prostate
cancerbetweenthetwogroupswastestedbydetermin-
ing the risk ratio for prostate cancer specific death.
We also performed a subgroup analysis of men with
a diagnosis in 1993 or later—that is, from the time that
prostate specific antigen testing was introduced in the
screeningarm.AllanalyseswereperformedwithSPSS
18.0.
The main outcome measure was the prostate cancer
specific death risk ratio. The study was designed to
detect a plausible reduction of prostate cancer specific
mortality within 20 years from the start of the study
from 1.5% to 1.0% in the screening group. A total of
1050patientsinthescreeninggroupwouldberequired
to detect this difference (80% power, two sided 5% sig-
nificance level). To allow for non-compliance in the
screening group and contamination in the control
group,1400menwereincludedinthescreeninggroup.
Nointerimanalyseswithmortalityasendpointwere
performed.
RESULTS
In 1987, 1161 of 1492 (78%) invited men underwent
screening. The numbers were 957/1363 (70%) in 1990
and895/1210(74%)in1993.In1996,menbornbefore
1927 (n=512) were not invited to screening, leaving
606 men born 1927-37. Of these, 446 (74%) attended
the screening. The median follow-up time was
75 months.
Eightyfivecases(5.7%)ofprostatecancerwerediag-
nosedinthescreenedgroupand292(3.9%)inthecon-
trol group (table 1). In the intervention group, 43
tumourswerefoundatscreeningand42intheinterval
between examinations (table 2). The percentage of
men with localised tumours (T1-2, N0/NX, M0) was
significantly higher in the screened group (56.5%)
than in the control group (26.7%, P<0.001). The rates
of non-localised tumours were 37/1494 (2.5%) in the
screening group and 213/7532 (2.8%) in the control
group (P=0.44).
The prostate cancer specific mortality was 30/85
(35%) for men with prostate cancer diagnosed in the
screeninggroupand130/292(45%)formenwithpros-
tatecancerdiagnosedinthecontrolgroup.Theoverall
mortality for men with prostate cancer was 69/85
(81%) in the screening group and 252/292 (86%) in
thecontrolgroup.Themediancancerspecificsurvival
was201monthsinthescreenedgroupand133months
inthecontrolgroup.Theriskratiofordeathfrompros-
tate cancer was 1.16 (95% confidence interval 0.78 to
1.73).
The log rank test did not show a significantly longer
prostate cancer survival (P=0.065) or overall survival
(P=0.14)formenwithprostatecancerdiagnosedinthe
screening group (figs 2 and 3). Figure 4 shows the
cumulative mortality. In a Cox proportional hazard
analysis, the hazard ratio for death from prostate can-
cer was 1.23 (0.94 to 1.62; P=0.13) and 1.58 (1.06 to
2.36; P=0.024) after adjustment for age at start of the
study. With the addition of the period of diagnosis as
1987-92 or 1993-9 as a dichotomous time dependent
variableandadjustmentforageatthestartofthestudy,
the hazard ratio was 1.59 (1.07 to 2.38; P=0.022). The
period of diagnosis as a time dependent variable was
not found to be a significant covariate in univariate
analysis.
Table 1 |Baseline data and mortality in men allocated to screening for prostate cancer or no
screening (control group)
No screening group Screening group
Noofmen(excludingmenwithprostatecanceralreadydiagnosed) 7532 1494
Age (years):
50-54 1790 357
55-59 1809 360
60-64 2004 393
65-69 1929 384
No (%) of prostate cancers diagnosed, 1 January 1987
to 31 December 1999
292 (3.9) 85 (5.7)*
Mean (SD) age at diagnosis (years) 69.7 (5.7) 68.1 (5.6)†
*43 (2.9%) detected at screening; 42 (2.58%) interval cancers.
†66.5 (5.2) in men with cancer detected at screening; 69.9 (5.5) in men with interval cancers.
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Fig 3 | Kaplan-Meier curves of prostate cancer specific survival
for men diagnosed with prostate cancer in control group
(n=292) and screened group (n=85). Log rank test P=0.065
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In this randomised controlled trial, screening for pros-
tate cancer did not seem to have a significant effect on
mortalityfromprostatecancerafter20yearsoffollow-
up.Therelativelyhighcancerspecificmortalityseenin
men with localised prostate cancer if they are followed
up for long enough
12 makes not only the large sample
sizebutalsoasufficientlylongfollow-uptimeprerequi-
sites for accurate interpretation of mortality data.
Strength of this study
The high compliance, uniform treatment, and com-
plete data on tumour stage, tumour grade, and cause
of death provided by the South-East Region Prostate
Cancer Register and the Central Death Register all
givestrengthtoourfindings.Thepersonalregistration
number unique for each Swedish citizen
10 minimises
the risk of dropouts and incomplete data because of
change of address.
The completeness of the National Cancer Register
has also been found to be high,
13 which supports the
validityoftheSouth-EastRegionProstateCancerReg-
ister. A validation of the South-East Region Prostate
Cancer Register showed a high accuracy and comple-
teness for all variables included.
14
The extended prostate cancer registration, which
covered the screened group as well as the control
group, provided data on tumour stage, tumour grade,
treatment, and mortality for both groups.
14 All men
with a diagnosis of prostate cancer, whichever group
they were allocated to, underwent the same standar-
dised management programme. Uniform principles
for registration, evaluation, and treatment decision
minimise the risk of bias caused by local variations in
management.Allmeninthescreeninggroupaswellas
inthecontrolgroupweremanagedinthesameurology
unit.Theincidenceofprostatecancerwashigherinthe
screening group, probably because of detection of a
larger number of indolent tumours that do not reduce
prostate cancer specific survival or overall survival.
Comparison with other studies
Opportunisticscreeningforprostatespecificantigenis
not practised as widely in Sweden as in the United
States.
15-17 Until 1994, less than one test per man aged
50 or older was performed in Sweden.
18 The relatively
low level of such testing in the background population
reducedthechanceofcontaminationaswellasthepre-
valence of undetected indolent tumours in the screen-
ing group before the start of the study. The study
started before testing was introduced in clinical
practice,
18 which could have increased the lead time
even more. Until 1987, prostate cancer was diagnosed
almost exclusively at presentation with symptoms or
incidentally at histopathological examination after
transurethral prostate resection. The pre-screening
prevalence of asymptomatic low grade tumours was
therefore low.
Although screening with digital rectal examination
and prostate specific antigen is an effective method for
detecting early stages of prostate cancer, the high rate
of overdiagnosis has to be considered before
Table 2 |Distribution of tumour stage, tumour grade, and treatment in men with prostate cancer according to allocation to
screening or no screening (control). Figures are numbers (percentages)
No screening group
Screening group
All cancers Cancers detected at screening Interval cancers
Tumour stage:
Localised tumours (T1-2, N0/NX, and M0) 78 (26.7) 48 (56.5) 36 (83.7) 12 (28.6)
Advanced tumours (T3-4, N1, or MX/M1) 213 (73.3) 37 (43.5) 7 (16.3) 30 (71.4)
Tumour grade:
G1 94 (32.2) 43 (50.6) 24 (55.8) 19 (45.2)
G2 149 (51.0) 31 (36.5) 19 (44.2) 12 (28.6)
G3 43 (14.7) 11 (12.9) 0 (0) 11 (26.2)
GX/tumour grade not recorded 6 (2.1) 0 (0) 0 (0) 0 (0)
Treatment:
Watchful waiting 101 (34.6) 37 (43.5) 21 (48.8) 16 (38.1)
Hormonal treatment 147 (50.3) 27 (31.8) 4 (9.3) 23 (54.8)
Radical prostatectomy 23 (7.9) 16 (18.8) 14 (32.6) 2 (4.8)
Brachytherapy 3 (1.0) 1 (1.2) 0 (0) 1 (2.4)
External radiotherapy 15 (5.1) 4 (4.7) 4 (9.3) 0 (0)
Not registered 3 (1.0) 0 (0) 0 (0) 0 (0)
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Fig 4 | Cumulative rates of prostate cancer specific mortality
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screening.
19Atthestartofthistrial,digitalrectalexam-
inationandfineneedleaspirationbiopsywereusedfor
tumour detection. Despite the fact that these methods
have a lower sensitivity than prostate specific antigen
testing and ultrasound guided biopsy, there was a sig-
nificant shift towards detection of localised tumours in
the intervention group.
9 The rate of diagnosis in the
screened group, however, was lower than in the
PLCO and ERSPC trials.
2-4
Diseasespecificmortalityisoneofthemostsensitive
measures of the aggressiveness of a disease and the
effectiveness of treatment. Determination of disease
specificmortality,however,requiresaccuratedetermi-
nation of the underlying cause of death. In a review of
the medical records of patients in the South-East
Region Prostate Cancer Register, the validity of the
death certificates that constitute the base for the cause
ofdeathwasshowntobehigh.
20Thisalsosupportsthe
outcomeofourstudyaswedetermineddiseasespecific
mortality from the South-East Region Prostate Cancer
Register. Although the data in the ERSPC, as well as
trials, have been carefully validated,
21 the criteria for
defining death in prostate cancer are more vaguely
defined.
The impact of screening on stage shift has been
described in a previous report.
9 The tumours in the
screeninggroupweresmallerandmoreoftenlocalised
than in the control group. In contrast with the PLCO
and ERSPC trials,
21 we had complete data on tumour
stage for all men in the control group and the screened
group.Thescreeninghadhighacceptanceinthepopu-
lation and a reasonable cost.
78 The actual cost of the
tests, however, is only a part of the total cost of
screening.
822 The total healthcare costs for prostate
cancertreatmentandotherrelevantcostsinhealthcare
and in society should also be taken into consideration
before the introduction of a widespread screening
programme.
Thepopulationsizeinourstudywassmallerthanthe
PLCO and ERSPC trials, but the longer follow-up,
highattendance,andlowrateofcontaminationcaused
the power to reach a similar level. The risk ratio for
prostate cancer specific death in our study (1.16, 0.78
to1.73)wasclosetothatfoundinthePLCOtrial(1.13,
0.75 to 1.70). The confidence interval of the risk ratio
was narrow enough to conclude that screening and
treatment of men with tumours detected through
screening as practised in the present study is unlikely
toreduce mortality fromprostatecancerby more than
a third. Though screening could lead to a reduction of
up to a third in mortality from prostate cancer, this
would be at the risk of overdetection and
overtreatment.
9
Although the outcomes are somewhat contradic-
tory, the results of our study and the PLCO and
ERSPC studies indicate that, whether or not there
might be a benefit from prostate cancer screening, a
high rate of overdiagnosis is unavoidable.
2-4 In the
ERSPC trial, it was estimated that screening for pros-
tate cancer could advance the diagnosis by 10 years.
Half of the cancers detected by screen would not
have been diagnosed in the absence of screening.
2223
To prevent one death from cancer, 1410 men would
need to be screened and 48 treated.
3
Policy implications
Before undergoing prostate specific antigen testing,
asymptomatic men should be informed about the
potential hazards of treatment with curative intent in
case prostate cancer is diagnosed. These include erec-
tile dysfunction, urinary incontinence, and bowel
symptoms. The discomfort associated with prostate
biopsy and the psychological effects of false positive
results should also be considered.
24 The next goal for
prostate screening shouldrather be to find ways of dis-
criminating indolent tumours from high risk tumours
and to develop less aggressive treatment for indolent
tumours
25 rather than to optimise sensitivity of the
diagnostic tests.
Conclusions
Theriskratioforprostatecancerspecificdeathdidnot
indicate significant benefit from prostate cancer
screening. Although the population size in our study
is not sufficient to draw definite conclusions, the
power is sufficient to show major differences in pros-
tate cancer specific survival.
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